A well-timed bridge investment can mean the difference between stalling and scaling. Dr. Asel Sartbaeva, CEO and co-founder of EnsiliTech, reflects on how family office support provided crucial bridge, enabled better deal terms, and positioned the company to close an oversubscribed £4.5 million round.

Machine learning is reshaping discovery science in Human Health and Organicin Scientific is proving its potential in animal health too. Mat Mitchell, Co-Founder and CTO, shares how Organicin Scientific’s machine-learning platform automates candidate selection to identify, evaluate, and commercialise novel antimicrobials for safe and sustainable use across the industry.

During the presentation, I’ll describe how innovation rarely follows a linear path, and how technology delays and regulatory change require decisions to be revisited after capital has already been deployed — with a focus on maintaining strategic intent and building value for investors.

With resistance to existing parasiticides rising and few new molecules in decades, ASTRA Therapeutics set out to change the game. Co-CEOs Natacha Gaillard and Ashwani Sharma share how the company closed one of the largest seed rounds in animal health, positioned itself to deliver precision-designed antiparasitics, and built investor confidence in solving one of animal health’s most urgent challenges.